333 related articles for article (PubMed ID: 30877177)
1. Accuracy of
Valkema MJ; Noordman BJ; Wijnhoven BPL; Spaander MCW; Biermann K; Lagarde SM; Bennink RJ; Schreurs WMJ; Roef MJ; Hobbelink MGG; Janssen MJR; Graven LH; van Lanschot JJB; Valkema R
J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Clinically Complete Responders Using Serial
Valkema MJ; van der Wilk BJ; Eyck BM; Wijnhoven BPL; Spaander MCW; Doukas M; Lagarde SM; Schreurs WMJ; Roef MJ; van Lanschot JJB; Valkema R
J Nucl Med; 2021 Apr; 62(4):486-492. PubMed ID: 32887759
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
[TBL] [Abstract][Full Text] [Related]
5. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
[TBL] [Abstract][Full Text] [Related]
6. 18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy.
Valkema MJ; de Lussanet de la Sablonière QG; Valkema R; Thomeer MGJ; Dwarkasing RS; Harteveld AA; Doukas M; Mostert B; van der Zijden CJ; van der Sluis PC; Lagarde SM; Wijnhoven BPL; Verburg FA; van Lanschot JJB
Nucl Med Commun; 2024 Feb; 45(2):128-138. PubMed ID: 37982560
[TBL] [Abstract][Full Text] [Related]
7. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.
Eyck BM; Onstenk BD; Noordman BJ; Nieboer D; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Ann Surg; 2020 Feb; 271(2):245-256. PubMed ID: 31188203
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
11.
Avallone A; Aloj L; Pecori B; Caracò C; De Stefano A; Tatangelo F; Silvestro L; Granata V; Bianco F; Romano C; Di Gennaro F; Budillon A; Petrillo A; Muto P; Botti G; Delrio P; Lastoria S
J Nucl Med; 2019 Nov; 60(11):1560-1568. PubMed ID: 30877175
[TBL] [Abstract][Full Text] [Related]
12. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
[TBL] [Abstract][Full Text] [Related]
14. Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer.
Kroese TE; Ruurda JP; Bakker AS; Jairam J; Mook S; van der Horst S; Meijer GJ; Haj Mohammad N; van Rossum PSN; van Hillegersberg R
Clin Nucl Med; 2022 Jun; 47(6):496-502. PubMed ID: 35384907
[TBL] [Abstract][Full Text] [Related]
15. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
[TBL] [Abstract][Full Text] [Related]
16. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
Vollenbrock SE; Voncken FEM; Lambregts DMJ; Maas M; Donswijk ML; Vegt E; Ter Beek LC; van Dieren JM; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):176-185. PubMed ID: 32572560
[TBL] [Abstract][Full Text] [Related]
17. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using
Goense L; Ruurda JP; Carter BW; Fang P; Ho L; Meijer GJ; van Hillegersberg R; Hofstetter WL; Lin SH
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1742-1751. PubMed ID: 29663014
[TBL] [Abstract][Full Text] [Related]
18. FDG PET using SUV
Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.
van der Bogt RD; Noordman BJ; Krishnadath KK; Roumans CAM; Schoon EJ; Oostenbrug LE; Siersema PD; Vleggaar FP; van Lanschot JJB; Spaander MCW
Endoscopy; 2019 Apr; 51(4):326-332. PubMed ID: 30497088
[TBL] [Abstract][Full Text] [Related]
20. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]